| Index | — | P/E | — | EPS (ttm) | -15.44 | Insider Own | 20.07% | Shs Outstand | 68.58M | Perf Week | 1.89% |
| Market Cap | 962.11M | Forward P/E | 9.83 | EPS next Y | 1.43 | Insider Trans | 0.00% | Shs Float | 67.96M | Perf Month | 30.27% |
| Enterprise Value | 3.92B | PEG | — | EPS next Q | 0.20 | Short Float | 19.12% | Perf Quarter | -20.19% | ||
| Income | -1.05B | P/S | 0.36 | EPS this Y | -62.91% | Short Ratio | 7.91 | Perf Half Y | 12.96% | ||
| Sales | 2.67B | P/B | 0.54 | EPS next Y | 85.11% | ROA | -18.34% | Short Interest | 12.99M | Perf YTD | -50.88% |
| Book/sh | 25.88 | P/C | 7.82 | EPS next 5Y | 3.93% | ROE | -55.30% | 52W High | 35.58 -60.57% | Perf Year | -47.67% |
| Cash/sh | 1.79 | P/FCF | — | EPS past 3/5Y | — | ROIC | -16.05% | 52W Low | 9.92 41.43% | Perf 3Y | -77.49% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | -5.80% 10.43% | Gross Margin | 44.60% | Volatility | 7.05% 8.32% | Perf 5Y | -89.54% |
| Dividend TTM | — | EV/Sales | 1.46 | EPS Y/Y TTM | — | Oper. Margin | -30.67% | ATR (14) | 1.03 | Perf 10Y | -34.13% |
| Dividend Ex-Date | — | Quick Ratio | 0.76 | Sales Y/Y TTM | -2.44% | Profit Margin | -39.20% | RSI (14) | 57.29 | Recom | 2.73 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.39 | EPS Q/Q | 8.33% | SMA20 | 4.15% | Beta | 0.77 | Target Price | 12.25 |
| Payout | 0.00% | Debt/Eq | 1.73 | Sales Q/Q | 2.77% | SMA50 | 10.10% | Rel Volume | 1.57 | Prev Close | 13.25 |
| Employees | 6,500 | LT Debt/Eq | 1.51 | Earnings | Nov 03 | SMA200 | -13.14% | Avg Volume | 1.82M | Price | 14.03 |
| IPO Date | Feb 01, 1991 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 366.16% 1.97% | Net Debt/EBITDA | — | Volume | 2,856,165 | Change | 5.89% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-07-26 | Reiterated | UBS | Neutral | $17 → $12 |
| May-07-26 | Downgrade | Jefferies | Buy → Hold | $13 |
| Apr-10-26 | Reiterated | UBS | Neutral | $30 → $17 |
| Feb-12-26 | Reiterated | UBS | Neutral | $35 → $30 |
| Jan-21-26 | Reiterated | UBS | Neutral | $50 → $35 |
| Oct-07-25 | Downgrade | Citigroup | Buy → Neutral | |
| May-08-25 | Upgrade | Jefferies | Hold → Buy | |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy | |
| Sep-19-24 | Reiterated | UBS | Sell | $50 |
| Sep-05-24 | Reiterated | Craig-Hallum | Hold | $57 |
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/28/2025 | FY 2024 12/29/2024 | FY 2023 12/31/2023 | FY 2022 1/1/2023 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,675 | 2,730 | 2,783 | 2,998 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,481 | 1,456 | 1,496 | 1,501 | — | — | — | — | — | |
| Gross Profit | 1,193 | 1,274 | 1,287 | 1,497 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 770 | 746 | 767 | 763 | — | — | — | — | — | |
| Research and Development | 182 | 186 | 219 | 247 | — | — | — | — | — | |
| Other Operating Expense | 1,061 | 1,261 | 2,261 | 348 | — | — | — | — | — | |
| Operating Income | -820 | -919 | -1,961 | 139 | — | — | — | — | — | |
| Interest Expense | 195 | 178 | 188 | 179 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -15 | -11 | 18 | 11 | — | — | — | — | — | |
| Net Income Before Taxes | -1,029 | -1,108 | -2,131 | -29 | — | — | — | — | — | |
| Income Taxes | 18 | 24 | -79 | -19 | — | — | — | — | — | |
| Consolidated Net Income | -1,049 | -1,132 | -2,052 | -10 | — | — | — | — | — | |
| Net Income From Continuing Operations | -1,049 | -1,132 | -2,052 | -10 | — | — | — | — | — | |
| Net Income | -1,049 | -1,132 | -2,052 | -10 | — | — | — | — | — | |
| EPS (Recurring) | -15.44 | -16.69 | -30.54 | -0.15 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -15.44 | -16.69 | -30.54 | -0.15 | — | — | — | — | — | |
| EPS (Diluted) | -15.44 | -16.69 | -30.54 | -0.15 | — | — | — | — | — | |
| EBITDA | -383 | -488 | -1,490 | 607 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.36 | 0.73 | 1.07 | 1.65 | — | — | — | — | — | |
| Gross Margin | 44.60 | 46.67 | 46.25 | 49.93 | — | — | — | — | — | |
| Operating Margin | -30.65 | -33.66 | -70.46 | 4.64 | — | — | — | — | — | |
| Net Margin | -39.21 | -41.47 | -73.73 | -0.33 | — | — | — | — | — | |
| Shares Outstanding | 68 | 68 | 67 | 67 | — | — | — | — | — | |
| Market Capitalization | 954 | 1,992 | 2,965 | 4,938 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Siegrist Jonathan Philip | EVP of R&D & CTO | Oct 15 '26 | Option Exercise | 0.00 | 18,657 | 0 | 32,076 | Oct 19 |
| Bowman Ronald Lee | Chief Human Resources Officer | Sep 15 '26 | Option Exercise | 0.00 | 2,566 | 0 | 5,941 | Sep 17 |
| Hanson Bryan Michael | EVP Global Port. Mgmt & Mkting | Aug 15 '26 | Option Exercise | 0.00 | 446 | 0 | 8,217 | Aug 18 |
| Hanson Bryan Michael | EVP Global Port. Mgmt & Mkting | Jul 01 '26 | Option Exercise | 0.00 | 5,797 | 0 | 9,867 | Jul 02 |
| WIDDER KENNETH J | Director | Jun 06 '26 | Option Exercise | 0.00 | 1,183 | 0 | 0 | Jun 09 |
| POLAN MARY LAKE PH D | Director | Jun 06 '26 | Option Exercise | 0.00 | 973 | 0 | 0 | Jun 09 |
| BUECHLER KENNETH F | Director | Jun 06 '26 | Option Exercise | 0.00 | 2,156 | 0 | 0 | Jun 09 |
| Michael Edward L. | Director | Jun 06 '26 | Option Exercise | 0.00 | 1,252 | 0 | 0 | Jun 09 |
| Strobeck Matthew | Director | May 29 '26 | Option Exercise | 0.00 | 6,829 | 0 | 0 | Jun 02 |
| WIDDER KENNETH J | Director | May 29 '26 | Option Exercise | 0.00 | 6,829 | 0 | 0 | Jun 02 |
| POLAN MARY LAKE PH D | Director | May 29 '26 | Option Exercise | 0.00 | 6,829 | 0 | 0 | Jun 02 |
| BUECHLER KENNETH F | Director | May 29 '26 | Option Exercise | 0.00 | 6,829 | 0 | 0 | Jun 02 |
| Chiminski John R | Director | May 29 '26 | Option Exercise | 0.00 | 6,829 | 0 | 0 | Jun 02 |
| Huennekens R Scott | Director | May 29 '26 | Option Exercise | 0.00 | 6,829 | 0 | 0 | Jun 02 |
| Wilkins Joseph D Jr. | Director | May 29 '26 | Option Exercise | 0.00 | 6,829 | 0 | 0 | Jun 02 |